Short-term efficacy of intra-articular injection, PRP(platelet rich plasma) compared with placebo in patients with osteoarthritis of the knee

Short-term efficacy of intra-articular injection, PRP(platelet rich plasma) compared with placebo in patients with osteoarthritis of the knee in Zanjan province

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016030626922N1

Enrollment

Registered

2016-04-08

Start date

2015-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis. osteoarthritis

Interventions

injection A:PRP B:normal salin.

Placebo

injection A:PRP B:normal salin

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: This study will be conducted in Vali-Asr Hospital Rheumatology Clinic of men and women in the age range 30-70 years with osteoarthritis of the America College of Rheumatology classification criteria (ACR) shall be verified and if both diseases with a severely infected knee and the severity of patients in radiology 3-2 (moderately severe) will be examined. There is pain in patients with osteoarthritis of the knees and feel Krypytasyvn detailed mechanical examinations and x-rays are symptoms. Exclusion criteria included osteoarthritis secondary to inflammatory diseases - osteoarthritis generalized - osteoarthritis with grade 1 and 4 - metabolic bone - back pain - patients during the last 3 months any intra-articular injection have or arthroscopy during the past year have had. Any severe deformity of the knee - the knee varus and valgus knee more than 5 degrees more than 5 degrees - associated diseases such as septic knee - tumor - Crystal arthropathy or stiff joint effusion - anticoagulant treatment of patients with Hb less than 10 - dysfunction platelets or blood platelet count less than 150,000 liters in Mbkrv is also pregnancy- older than 70 years of sustainable use of NSAIDS in the past 48 hours, systemic disease, such as ischemic heart disease - diabetes and hepatitis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The severity of joint pain. Timepoint: 4-6week. Method of measurement: Patient interview questionnaire WOMAC + VAS.;The severity of stiffness. Timepoint: 4-6 week. Method of measurement: Patient interview questionnaire WOMAC + VAS.;Severity of joint dysfunction. Timepoint: 4-6 week. Method of measurement: Patient interview questionnaire WOMAC + VAS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contacttayebe lakzaei

Zanjan university of medical sciences

Dr.lakzaei55@zums.ac.ir+243 30 23236

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026